This program is supported by an independent educational grant from Amicus Therapeutics. This education program is designed for healthcare professionals globally (excluding the USA).
Join Pompe disease experts Prof. Pascal Laforêt and Prof. John Vissing for this accredited, interactive 60-minute teaching session exploring real-world strategies to enhance the recognition, monitoring, and individualized treatment of late-onset Pompe disease (LOPD). Through dynamic case-based discussion, faculty will unpack practical decision points in early detection, interpretation of subtle progression, and shared therapeutic planning aligned with current global frameworks. This program also includes an interview with a patient advocate from the Pompe Support Network, Kevin Annesley.
Accreditation: 1.0 CME Credit
Session highlights
- Improve early recognition of heterogeneous LOPD phenotypes, including respiratory-only, axial-dominant, and presymptomatic presentations
- Incorporate multimodal monitoring—quantitative MRI, diaphragm ultrasound, and digital metrics—to identify subclinical progression and guide individualized therapy
- Apply the European Triple-S framework to support evidence-based initiation, switching, or discontinuation of therapy
- Engage directly with expert faculty through a moderated Q&A
Who Should Attend?
This program is designed for global healthcare professionals involved in the diagnosis and management of Pompe disease, including:
- Neuromuscular Specialists
- Geneticists
- Neurologists
- Lysosomal Disease Specialists
- Respiratory Physicians, Genetic
- Counselors
- Pediatricians
- Other healthcare professionals involved in Pompe Disease
Faculty
Prof. Pascal Laforêt
A leading neuromuscular specialist at the Pitié-Salpêtrière University Hospital (Paris), Prof. Laforêt is internationally recognized for his clinical and research expertise in metabolic myopathies, including Pompe disease. He has led major natural-history studies, therapeutic trials, and guideline initiatives shaping modern LOPD diagnosis and management.
Prof. John Vissing
Director of the Copenhagen Neuromuscular Center and Professor of Neurology at the University of Copenhagen. Prof. Vissing is a global authority on inherited myopathies and innovative diagnostic technologies, with extensive experience in clinical trials, quantitative imaging, and multidisciplinary models of care for Pompe disease and related disorders.
Kevin Annesley
A patient advocate with the Pompe Support Network. Since his diagnosis in 2008, Mr Annesley has participated in several clinical trials and serves as a Community Advisory Board (CAB) member for the International Pompe Association (IPA).
Program Schedule:
15 min - Prof. John Vissing
Recognise the heterogeneous, progressive, and multi-systemic nature of late-onset Pompe disease (LOPD) and embed multidisciplinary diagnostic pathways that prevent irreversible muscle loss.
35 min - Prof. Pascal Laforêt
Employ holistic, multimodal monitoring, including quantitative imaging, diaphragm assessment, and digital function metrics, to uncover subclinical progression and individualise supportive or pharmacologic optimisation in “stable” LOPD.
Apply the European Triple-S framework and the growing comparative-effectiveness evidence to facilitate shared decision-making on initiation, transition, or discontinuation of LOPD therapies.
10 min - Questions and Answers
20 min - Patient Advocate interview
Faculty Disclosure Statement / Conflict of Interest
In compliance with EBAC guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CE activities.
Pascal Laforêt, MD, PhD has disclosed financial relationships within the past 36 months with the following ineligible companies: Consultant/Strategic advice/Advisory Board for Amicus Therapeutics, Astellas, Sanofi, Shionogi. Grant/Research Support from Amicus Therapeutics, Astellas, Sanofi. Educational Activities honoraria with Atticus, Sanofi
John Vissing, MD, PhD has no financial interests, relationships, or affiliations in relation to this activity.
Kevin Annesley has no financial interests, relationships, or affiliations in relation to this activity.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the European Board for Accreditation of Continuing Education for Health Professionals (EBAC)
MedAll is an EBAC accredited provider since 2025. The European Board for Accreditation of Continuing Education for Health Professionals (EBAC) accredits Continuing Education (CE) programmes for the international medical community.
This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 1 hour of effective education time.
EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of participation in an activity eligible for conversion of credit to AMA PRA Category 1 Credit.
The Accreditation Council for Continuing Medical Education (ACCME) and the Royal College of Physicians and Surgeons of Canada hold an agreement on substantial equivalency of accreditation systems with EBAC.
EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).
Participation Costs
There is no cost to participate in this program.
Requirements for Completion
To receive credit, participants must complete the full activity, the post-test, and the evaluation form before the stated expiration date. There are no prerequisites, and there is no fee to participate or claim credit. A Certificate of Completion will be issued upon successful completion of all required components.
A minimum passing score of 70% on the post-test is required. Participants should consult their own professional licensing authority regarding eligibility to claim credit for this educational activity.
EBAC® only awards CE certificates in increments of 1.0 credit.
Launch and Expiration Date: 18 February 2026 – 18 February 2026
Estimated time to complete this activity: 60 minutes
System Requirements
Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.
Disclosure of Unlabelled Use
This certified continuing medical education (CME) activity may contain discussion of unlabeled or investigational uses of commercial products or devices. In accordance with applicable standards, all faculty are required to disclose any planned discussion of unlabeled or investigational uses. Such discussions are intended solely for educational purposes and must not be construed as recommendations for clinical use.
Learners are advised to review the prescribing information for each product, including indications, contraindications, warnings, and approved uses as approved by relevant regulatory authorities.
The accredited provider does not endorse the use of any product outside the approved labeling.
Clinical decisions should always be made based on current evidence, official guidance, and the clinician’s professional judgment.
Disclaimer
This activity is intended for educational purposes only and does not establish a standard of care or replace clinical judgment. Any therapeutic or diagnostic strategies discussed must be evaluated in the context of each patient’s clinical circumstances, risks, and current evidence.
Learners should consult authoritative clinical guidelines and approved product information when considering treatment decisions.
All materials are used with permission. The views expressed are those of the faculty and do not necessarily reflect those of the accredited providers, MedAll, or any supporters.
Content is accurate as of the date of release.